Hi [[ session.user.profile.firstName ]]

Why the success of your HTA will rely on real world evidence

The first in a trilogy of webinars focussed on the topic; Unlocking the value; the economic equation and part of the IMS Health Practical Insights series.

While it remains the gold standard, the feasibility of large scale randomised clinical trials within a pipeline that is ever more focused on niche and personalised medicines is decreasing – particularly in the fields of rare diseases and oncology. Within the changing landscape of drug development, payers need robust evidence in order to accurately assess the value and efficacy of innovative treatments for both smaller patient populations and increasingly expensive medicines. Answering this paradigm is where real world evidence can step in.
Topics covered include:
•The HTA landscape – the challenges of assessing rare disease and cancer medicines
•How regulators consider RWE in HTAs
•Learnings from best practice in global markets
•Recent case studies – successes and failures
•The role of the regulator in the Cancer Drugs Fund
•How RWE can assist market access
Recorded Feb 11 2016 69 mins
Your place is confirmed,
we'll send you email reminders
Presented by
Adam Lloyd, Eric Yu, Rita Faria
Presentation preview: Why the success of your HTA will rely on real world evidence

Network with like-minded attendees

  • [[ session.user.profile.displayName ]]
    Add a photo
    • [[ session.user.profile.displayName ]]
    • [[ session.user.profile.jobTitle ]]
    • [[ session.user.profile.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(session.user.profile) ]]
  • [[ card.displayName ]]
    • [[ card.displayName ]]
    • [[ card.jobTitle ]]
    • [[ card.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(card) ]]
  • Channel
  • Channel profile
  • Drug development and how best to work with specialised Rare Disease networks Nov 9 2021 12:00 pm UTC 60 mins
    Dr Jean-Meidi Alili, senior pharmacist at G2M; Dr Jeff Keefer, IQVIA; Dr Joanne Hackett, IQVIA; Dominic Tyer, pharmaphorum
    This webinar will take place on Tuesday 9th November at 12:00 pm GMT / 1:00 pm CET.

    Far more common than initially thought, rare disease treatments remain far too scarce. The answer to the problem, of course, lies in making both academic and commercial medical research more efficient and effective.

    This webinar will share more information about how to work more collegially with academics, industry and patient groups to ultimately improve the care and treatment of patients with rare diseases.
  • The digital transformation of pharma’s physician engagement strategies Recorded: May 19 2021 59 mins
    Anupam Nandwana, CEO, P360; Florent Edouard, commercial excellence, Grünenthal; Dr Mehra, physician, medical journalist
    The exact shape of healthcare’s post-COVID ‘new normal’ is still being framed, but it is clear that some trends are already taking shape - and one of the key ones is digital transformation in pharma.

    This pharmaphorum webinar, held in association with P360, takes place on Wednesday 19th May 08:00 PST / 16:00 BST / 17:00 CET and will look at the long-term implications of healthcare’s pandemic-powered digital transformation.
  • Using AI to make a big impact for emerging and mid-sized biopharma companies Recorded: Apr 29 2021 60 mins
    Matthew Van Wingerden, GM, Aktana; Doug Caldwell, VP, Veeva Systems; Sal Paolozza, Director, Antares
    With recent market changes catalysing a rapid shift to an omnichannel approach, life science organisations of every size are racing to adapt their commercial approach to be more relevant, coordinated and personalised to the needs of each HCP.

    This pharmaphorum webinar, held in association with Aktana, will take place on 29th April 2021 at 15:00 BST / 10:00 EDT.
  • AI, big data and deep real-world evidence – the challenges and opportunities Recorded: Apr 22 2021 61 mins
    Dr Ignacio Medrano, Savana; Prof Jenni Quint, BREATHE; Prof Nawar Bakerly, Salford Royal NHS FT
    Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations and is accelerating the development of new and innovative therapies and treatments to improve patient outcomes.

    This pharmaphorum webinar, held in association with Savana, will take place on Thursday 22 April from 16:00-17:00 BST / 17:00-18:00 CET / 10:00-11:00 EST and hear from presenters at BREATHE - the Health Data Research Hub for Respiratory Health, Salford Royal NHS Foundation Trust and Savana.
  • Customer engagement and pharma’s field force future Recorded: Apr 14 2021 75 mins
    Vandana Singh, Axtria; Steve Green, Takeda; Dany Labrecque, Global Biopharma Independent Advisor; Mann Singh, Novo Nordisk
    How healthcare professionals prefer to engage with pharma companies has been changing for some time, and COVID’s digital transformation of society has dramatically accelerated this.

    This pharmaphorum webinar – in association with Axtria – will take place on Wednesday 14th April from 16:00-17:00 BST / 11:00-12:00 EDT and look at customer engagement and the future of pharma’s field force.
  • Virtual trials and the next generation of pharma clinical research Recorded: Mar 25 2021 72 mins
    Trishna Bharadia, Rosamund Round, PAREXEL, Martin Gibson, NorthWest EHealth, Yan Yiannakou, Consultant Gastroenterologist
    Previously viewed as a ‘nice to have’ for the pharma industry, virtual clinical trials were already moving from a theoretical to a practical proposition before COVID-19 accelerated their transition.

    This pharmaphorum webinar, held in association with the National Institute for Health Research (NIHR), will take place on Thursday 25th March 15:30 GMT / 16:30 CET and look at where virtual trials fit into the next generation of commercial clinical research.
  • Coordinating and delivering research in the pandemic: The UK approach Recorded: Feb 25 2021 74 mins
    Phil Troke, Gilead; Kirsty Wydenbach, MHRA; Terence Stephenson, HRA; Nick Lemoine, NIHR Clinical Research Network
    The acute phase of the COVID-19 pandemic tested the UK’s capacity and capability to rapidly deliver crucial clinical research at a time of immense pressure and stress on personnel and resources.

    This pharmaphorum webinar, held in association with the National Institute for Health Research (NIHR), will take place on Thursday 25th February 13:00 GMT / 14:00 CET and discuss the UK’s approach to delivering research during the COVID-19 pandemic.
  • Navigating the UK regulatory pathway to increase patient engagement with trials Recorded: Dec 16 2020 68 mins
    Gareth Powell, NIHR, Sophie Evett, Pfizer, Richard Stephens and Keith Wilson, Patient Advocates, Dominic Tyer, pharmaphorum
    Involving patients in clinical trial design can hugely benefit pharmaceutical research's sustainability.

    This pharmaphorum webinar, held in association with the National Institute for Health Research (NIHR), takes place on Wednesday 16th December, 11:00 GMT / 12:00 CET and will look at how to navigate the compliance pathway to increase patient engagement with clinical trials.
  • Introducing the new NIHR national Patient Recruitment Centres Recorded: Nov 12 2020 78 mins
    Helen Quinn, Dinesh Saralaya, Yan Yiannakou, Melanie Davies, Gavin Galasko, Dominic Tyer, pharmaphorum
    The five new NIHR national Patient Recruitment Centres (PRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects.

    This pharmaphorum webinar, held in association with the National Institute for Health Research (NIHR), takes place on Thursday 12th November, 14:00 GMT / 15:00 CET and will introduce the new NIHR national Patient Recruitment Centres and look at how the PRCs will take a patient-centric approach to pharmaceutical research.
  • Behavioural insights into haem/onc clinical decision-making Recorded: Sep 3 2020 65 mins
    Katie Lucero, Medscape Education; Victoria Harvey-Jones, Medscape Oncology Global; Prof Mohamad Mohty, Saint-Antoine Hospital
    With exclusive surveys of the continuing medical education (CME) needs of haematologists/oncologists (haem/oncs), this webinar will look at where physicians are going for their learning needs and what effect the COVID-19 pandemic continues to have.

    The Behavioural insights into haem/onc clinical decision-making webinar, in association with Medscape, will take place on Thursday 3rd September from 13:00-14:00 (BST)/14:00-15:00 (CEST).
  • How to win with a multichannel approach in pharma Recorded: Jul 1 2020 62 mins
    Birgitte Dreyer, Novo Nordisk, Oksana Matviienko, Viseven, Dominic Tyer, pharmaphorum [moderator]
    This webinar will look at how pharma can use modular content in its multichannel and omnichannel strategies.

    Presented in association with Viseven, it will also include ways to improve, and speed up, the content supply chain and hear how Novo Nordisk designs and executes customer engagement journeys
  • Accelerating your digital IQ for the next normal of customer engagement Recorded: Jun 25 2020 71 mins
    David Logue, Veeva, Aaron Bean, Veeva, Sierra Towers, Boehringer Ingelheim, Dominic Tyer, pharmaphorum
    COVID-19 has brought many changes to the pharmaceutical industry, among them a need to change how pharma companies engage with HCPs and transform their approach to digital channels.

    This webinar, held in association with Veeva, will present some exclusive market observations from before and during the COVID crisis and explain how pharmaceutical companies can increase their digital IQ and accelerate the move to digital.
  • Unlocking health data to improve oncology outcomes Recorded: Jun 23 2020 70 mins
    Professor Mick Peake, Leicester University, Thomas Lawrence, NICE, Yoshiko Cook, Adam Reich, IQVIA, Paul Tunnah, pharmaphorum
    As use of real-world evidence increases there is an opportunity to improve the patient experience.

    In addition to key steps forward with the establishment of Health Data Research UK and NHSX, information governance will be key, as is alignment to UK and EU regulations such as the July 2019 DHSC Framework for the Value of NHS Research and GDPR.
  • COVID-19 May Briefing: The UK&I Healthcare Ecosystem Fightback Recorded: May 27 2020 71 mins
    Professor Shafi Ahmed, Divya Chadha Manek, Rt Hon Stephen Dorrell, Angela McFarlane, Sarah Rickwood, Paul Tunnah (moderator)
    Insights on the impact of COVID-19 for pharma and biotech companies and considerations for a post-coronavirus new normal in life sciences and healthcare.

    It will also discuss the UK response to the emergency, clinical trials and how digital health has met the COVID-19 challenge for healthcare professionals, patients and industry.
  • 10 years in 10 days: the new global digital health paradigm in life sciences Recorded: Apr 29 2020 71 mins
    Roberto Ascione, Kristin Milburn, Healthware Group, Gerry Chillè, Healthware Labs, Ariel Salmang, Intouch International
    COVID-19 is making digital transformation even more pressing for pharmaceutical companies.

    Amid the coronavirus pandemic digital health offers many ways to develop public utility projects and enhance healthcare communications.
  • IQVIA COVID-19 April briefing: A deep dive on impacts for UK&I pharma + biotech Recorded: Apr 23 2020 68 mins
    Professor Mark Caulfield, Genomics England, Jonathan Sheffield, NIHR, Nancy Dreyer, Carol Alexandre, Sarah Rickwood, IQVIA

    This April webinar is part of IQVIA’s monthly updates on the impact of COVID-19 and its implications for the healthcare ecosystem.

    In the global effort to proactively fight COVID-19, the webinar series has been designed to:
    •Provide some areas which pharma and biotech companies may wish to consider around the COVID-19 outbreak, in order to help guide our community through uncertain times
    •Share key healthcare impact learnings from those countries that are ahead in the COVID-19 curve
    •Look at how we can, together, best support patients, healthcare professionals, life sciences and governments to reduce the impact of the virus

    This April webinar will take place on Thursday 23rd April from 12.30 to 13.30 (BST) / 07:30 to 08:30 (EST).

    You can listen to our March webinar here: https://pharmaphorum.com/r-d/the-potential-impact-of-coronavirus-covid-19-for-global-pharma-and-biotech-continuity/


    During the April instalment, our expert panel will discuss:
    •Assessing the pharmaceutical market impact of COVID-19
    •The UK clinical trials on COVID-19: navigating uncharted waters
    •Genomics: research in the time of COVID-19
    •Knowledge sharing: the COVID-19 experience from a US perspective
    •Getting clinical research back up and running post-coronavirus
    •Adjustments to new medicine launch planning
  • Vaccines trials in the COVID-19 era and tech’s role in speeding studies Recorded: Apr 8 2020 66 mins
    Chris Watson, Matthew McCarty, ERT, Nadeeka Dias, Paul Tunnah, CEO, pharmaphorum media
    This pharmaphorum webinar will take place on 8th April and comes as the COVID-19 outbreak has exposed the challenges pharmaceutical companies face as they race to develop a coronavirus vaccine.

    Thrown into even sharper relief than usual are the needs faced by all vaccine trials to balance study speed, data accuracy and patient experience.

    Additionally, given the fear of exposure and city mandates for individuals to stay at home, traditional patient recruitment challenges are exacerbated for a coronavirus trial. Placebo groups are unlikely to be used and the virus affects a very broad and non-discriminate patient population.

    So, what is technology’s role in supporting the faster evaluation of vaccines? The right data capture technology can provide some important ways to first speed up vaccines research and then gain quicker regulatory submissions, compared with traditional paper records.

    However, with patients’ expectations , it’s important to provide an experience of suitable quality to those who give up their time to take part in a study.

    The pharmaphorum webinar Vaccines trials in the era of COVID-19 – balancing study speed, accuracy and patient experience is being held in association with ERT.

    It is currently scheduled to take place on 8th April from 16:00 to 17:00 (BST) /11:00 to 12:00 (EST) and will look at how to balance trial speed, data accuracy and patient experience during the race for a coronavirus vaccine.

    Our expert panel will discuss:
    • Trial evolution so far and the impact of coronavirus
    • Specific challenges for trial sponsors working on a coronavirus vaccine
    • The impact of COVID-19 on patient attendance for studies
    • Patient experience in vaccines clinical trials
    • How to use virtual trial solutions, and when they’re not appropriate
    • Efficient capture of patient data and RWE in rapid deployment trials
  • The Potential Impact of Coronavirus (COVID-19) for Global Pharma and Biotech Con Recorded: Mar 18 2020 48 mins
    Sarah Rickwood, Rob Heathcote, Ben Hughes, Richard Gray, Howard Chen, IQVIA, Paul Tunnah, pharmaphorum
    Pharmaceutical and biotech companies around the globe are working with Governments to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges.

    Healthcare systems are being put under significant pressure, at a time when many are already over-stretched, medical congresses are being cancelled and bans on non-essential travel and enforced home working are emerging. Meanwhile, at local country level, Italy has gone into a country-wide lockdown and in China measures to prevent the virus’ spread have seen API manufacturing plants go offline.

    This pharmaphorum webinar, held in association with IQVIA, will take place on Wednesday 18th March from 12:30-13:30 GMT with expert speakers outline potential scenarios, considerations and decisions that pharma and biotech would wish to plan for.

    This COVID-19 continuity planning webinar will look at:
    •COVID-19's potential impact on global pharmaceutical market dynamics
    •Ways to support supply chain management
    •Maintaining open lines of communication with healthcare professionals
    •The application of artificial intelligence to potentially predict COVID-19 spread and patient infection
    •Learning from China
  • How ‘thinking modular’ might ease digital content overload in pharma Recorded: Mar 17 2020 65 mins
    Morten Kruse Sørensen, Novo Nordisk, Florent Edouard, Grünenthal Group, Huw Jenkins, Veeva, Kasper Jerlang, LEO Pharma
    In today’s digital world it is increasingly hard for pharmaceutical companies to successfully differentiate new brands based on their target product profile alone.

    Instead, the key factor now is often the quality of customer engagement, which more and more healthcare professionals (HCPs) appear to value.

    It’s enabled by a multichannel marketing (MCM) approach, but traditional MCM strategies require a much higher level of content than pharma is used to producing and approving – the answer to this is a modular approach.

    Such modular content allows pharma to meet HCPs’ information demands by leveraging content assets across multiple channels and in many different combinations, at the same time providing superior targeting and tracking.

    This pharmaphorum webinar, held in association with Anthill, will take place on Tuesday 17 March from 13:00 to 14:00 (GMT)/14:00 to 15:00 (CET) and will look at how the use of modular content in pharma can ease some digital worries.

    Our expert panel will discuss:

    •The most common challenges in the digital content creation process
    •Aligning content creation tactics with the multichannel marketing strategy
    •How to activate your existing content to maximise existing resource for the greatest HCP reach
    •Making the customer experience a key differentiator

    Our Panel
    •Morten Kruse Sørensen, Global Director Multichannel Excellence and Operations, Novo Nordisk
    •Florent Edouard, SVP, Global Head of Commercial Excellence, Grünenthal Group
    •Huw Jenkins, Director, DAM Strategy, Veeva
    •Kasper Jerlang, Head of Global Digital Marketing and Engagement, LEO Pharma
    •Tor Kristensen, CTO, Anthill Agency
    •Dominic Tyer, Creative and Editorial Director, pharmaphorum [moderator]
  • Applying behavioural interventions in chronic diseases Recorded: Feb 6 2020 62 mins
    Cara Blair, Robert Poole, Ian Greenway, Pippa Colden, Complete HealthVizion, Dominic Tyer, pharmaphorum
    Chronic diseases are the leading cause of death and disability worldwide and have a staggering impact on patients’ lives and the provision of healthcare around the world.

    Tackling conditions such as diabetes, heart disease and stroke is of vital importance if patient outcomes are to be improved and healthcare costs lowered.

    To achieve this, and in doing so address clinical inertia, a combination of innovative communication strategies and behavioural science can provoke small changes that produce a meaningful difference in health outcomes.

    This pharmaphorum webinar, in association with Complete HealthVizion, will look at how to help chronic disease patients to live well for longer, by providing a clear understanding of healthcare professionals’ and patients’ behaviours and communication needs.


    The webinar will take place on Thursday 6th February from 14:00-15:00 GMT/09:00-10:00 EST, when a world-class faculty representing a wide-range of disciplines, including social science, multichannel and medical affairs strategy, will discuss how behavioural change approaches can be used to avoid major health problems and the increasing costs associated with declining health.

    They will consider drivers of decision making in chronic disease management and look at why issues such as ‘behavioural complacency’ prevent progress and consider the lack of short-term benefits associated with many disease management approaches.

    All too often there is little urgency to act in patients at risk from chronic disease, despite a growing burden that increases their suffering and the time they spend in clinical practices with HCPs.

    This webinar will help change that, by looking at:

    •How to assess readiness to change among patients and HCPs
    •What strategic approaches work best in this setting
    •How to target the most important HCPs and convince them of the need for change
    •How to measure the effectiveness of behavioural change tactics
Thought leadership webinars within the pharmaceutical industry
pharmaphorum provides a digital podium for communicating thought leadership and innovation within pharma. Our webinars bring together different stakeholders from across the healthcare spectrum to drive fresh thinking and novel solutions that deliver better outcomes for patients.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Why the success of your HTA will rely on real world evidence
  • Live at: Feb 11 2016 2:00 pm
  • Presented by: Adam Lloyd, Eric Yu, Rita Faria
  • From:
Your email has been sent.
or close